SignalChem Lifesciences Corporation

December 20, 2013 16:29 ET

SignalChem Lifesciences Appoints New Chief Business Officer

Appointment reinforces company's commercialization goals

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 20, 2013) - SignalChem Lifesciences Corporation ("SLC" or the "Company"), developers of next generation kinase drugs, is pleased to announce the appointment of Dr. Akash Mathur to the position of Chief Business Officer. Dr. Mathur has a distinguished career in the biotechnology sector with more than 15 years experience. Prior to joining SLC, Dr. Mathur was the VP and Global Head, Business Development at Advinus Therapeutics (a Tata enterprise), a private CRO and therapeutics company. Dr. Mathur also co-led ProteoPlex, a startup microarray company, that was successfully acquired by Merck KGaA. He has extensive sales experience having led the training and development programs for sales groups of 3 different companies over the previous 13 years. Dr. Mathur has a successful track record in deal structuring, negotiations, evaluation of various financial models, development of patent portfolios and technology licensing. Dr. Mathur holds a PhD in Human Pathology with an emphasis on Hematology, Oncology, Protein Chemistry, and Enzymology from St. Louis University, a MS in Biophysics and BSc in Human Biology from All India Institute of Medical Sciences, and an MBA from Olin School of Business at the Washington University of St. Louis.

"The next 12 months are critical in SLC's path to commercialization as we focus on licensing 1-2 of our kinase programs," commented Dr. Jasbinder Sanghera, President and CEO. "In a short period of time, Akash has already made significant contributions in the development of our business plan. In addition, his access to key pharma and biotech partners puts SLC in position to deliver value to our shareholders."

"Having worked in the pharmaceutical space for over 15 years, including extensive studies in oncology, I am truly excited to help bring SLC's therapeutic programs to the market and deliver First-in-Class therapies to those people who are currently underserved by traditional methods," said Akash.

About SLC

SignalChem Lifesciences Corporation is a privately owned biopharmaceutical company specializing in the discovery and development of kinase inhibitors as innovative therapies for cancer, inflammation and neurological diseases. The Company has a robust Kinase Platform encompassing 450 kinase targets and assays for the development and commercialization of unique therapies in many diseases. This vast resource empowers SLC's scientists to identify novel drug candidates against kinase targets of interest. Another key part of SLC's Kinase Drug Development Platform is KineCore™, a kinase focused small molecule library that was designed and assembled in-house. For more information, refer to the Company's website at

About Kinase Inhibitors

Defects in kinases account for numerous medical conditions including cancer, inflammation and neurological diseases. Kinase inhibitors account for one of the fastest growing market segments in the therapeutic market place. Since the first kinase inhibitor imatinib was approved by FDA in 2001, 25 kinase inhibitors have been approved by FDA for the treatment of cancers and RA. In total, including upfront fees, milestones and royalty structures, kinase deals in excess of $15bn have been completed in the last 8 years alone.

Forward-Looking Statements and Information

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

Contact Information